Share this article
Share this article
ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ( CBMG or the Company ) today announced the completion of the merger (the Merger ) of the Company with CBMG Merger Sub Inc., a Delaware corporation ( Merger Sub ) and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ( Parent ), pursuant to the previously announced Agreement and Plan of Merger (the Merger Agreement ), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub.
Under the terms of the Merger Agreement, which was approved by the Company s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company s common stock, par value $0.001 per share (the Company Common Stock ), issued and outstanding immediately prior to the effective time of the Merger (the Effective Time ), other
/PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company s special meeting of stockholders held.
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger
News provided by
Share this article
Share this article
ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ( Company, CBMG, we or our ), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company s stockholders vote
FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the merger proposal ).
Press release content from Newswire. The AP news staff was not involved in its creation.
SAM 2.0 Treatment Provides Non-Surgical Pain Relief for Federal Employees and Veterans Suffering From Knee Arthritis
January 27, 2021 GMT
SAM therapy is effective non-invasive treatment for knee arthritis and ZetOZ System s SAM technology is now available to veterans and federal employees.
SAM therapy is effective non-invasive treatment for knee arthritis and ZetOZ System s SAM technology is now available to veterans and federal employees.
TRUMBULL, Conn. - January 27, 2021 - ( Newswire.com )
ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device and leader in the development of SAM technology, announces that federal employees on government insurance, including veterans, law enforcement, and first responders, can get access to non-surgical SAM treatment. A recent research study published in The Open Orthopaed
From the WebMD Archives
Jerry Wade used to love bird-watching with his wife, an avid birder. I m not a birder myself, but I like being active and getting out there with her, he says. Bird-watching puts you into natural areas and some rough terrain it s not an easy physical activity.
But in the fall of 2005, the 66-year-old Columbia, Mo., resident, who had retired in 2000 from a career in community development, started noticing pains and twinges in his knees. A visit to his doctor in January 2006 brought the diagnosis: osteoarthritis of the knees. Fortunately, Wade had a friend at the nearby University of Missouri, who told him that researchers there were testing exercise regimens for people with the condition. Wade signed on. He embarked on a supervised aerobic-exercise program three times a week and then added strength-training.